Vivus
Trademark details
Vivus® is a registered trademark used for Pharmaceuticals Used To Treat Sexual Dysfunction or To Maintain Male or Female Sexual Health and owned by Vivus, Inc.. Full trade mark registration details, registered images and more information below.
| Goods and/or Services: | Pharmaceuticals Used To Treat Sexual Dysfunction or To Maintain Male or Female Sexual Health |
| Serial Number: | 74410240 |
| Registration Number: | 2027362 |
| Filing Date: | Jul 6, 1993 |
|
Last Applicant(s)/ Owner(s) of Record | Vivus, Inc.1172 Castro St. |
| Related Products: | Pharmaceuticals |
Suppliers
Total : 1 View more »
Vivus, Inc. in Kamuela, Hawaii, USA
Edit this Company edit this company Vivus, Inc. 10 Pala Kahua Dr Kamuela, Hawaii 96743 USA tel: +1 8088827749 Description Noncommercial Research Organization...
Web Sites
powered by 
Total : 2,160,000 View more »
Vivus - Welcome
VIVUS, Inc. is a drug-development company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity and sexual health.
VVUS: Summary for VIVUS, Inc.- Yahoo! Finance
View the basic VVUS stock chart on Yahoo! Finance. Change the date range, chart type and compare VIVUS, Inc. against other companies.
VIVUS, Inc. - Overview
Corporate Profile. VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead ...
Careers - Vivus - Welcome
VIVUS, Inc. is a drug-development company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity and sexual health.
Web Sites
Total : 8 View more »
Drug Discovery and Development Magazine | Strategies & Technologies Driving Drug Discovery to Market
...30, 2012 11:11 am | News | Comments The Food and Drug Administration approved a new impotence drug, Vivus Inc.'s Stendra. Vivus is talking to potential marketing partners, or it may sell the drug to another company. TOPICS: Pharma...
Phentermine plus topiramate in the treatment of obesity – Authors' reply
...thelancet.com Vol 378 July 9, 2011 3 Vivus. FDA issues complete response letter to Vivus regarding new drug application for Qnexa. http...since July, 2010, when the FDA considered Vivus’s bid to gain approval for phentermine/topiramate...
The Lancet : Volume 379, Number 9819, 10 March 2012
...antiobesity drug Asher Mullard Preview | Full Text | PDF Close An FDA advisory panel has recommended approving Vivus's weight-loss drug, potentially paving the way for the first new obesity drug in the USA in 13 years. Asher Mullard reports...
Panel meeting prompts excitement for antiobesity drug
...advisory panel has recommended approving Vivus’s weight-loss drug, potentially paving...Administration (FDA) panel meeting about Vivus’s antiobesity therapy Qnexa at the end...consultant for drug developers including Vivus. Vivus’s Qnexa is a combination...
News and Blogs
Total : 562 View more »
Vivus Will Plummet If Qnexa Fails - Seeking Alpha
... ETFs | Macro View | Alerts Vivus Will Plummet If Qnexa Fails May 10...ABT, ARNA, MRK, PFE, RHHBY.PK Vivus (VVUS), a biotechnology company that...health is up roughly 150% year to date. Vivus has never had any revenues and operating...
FDA OKs VIVUS Inc s Fast acting Viagra Rival
... Send As Email Print FDA OKs VIVUS, Inc. (VVUS)'s Fast-acting Viagra...Calif., April 27, 2012 /PRNewswire/ -- VIVUS,Inc. (NASDAQ: VVUS) today...treatments of ED," said Peter Tam, president, VIVUS. "We believe that the PDE5 selectivity...
Vivus Shares Soar on Diet Drug Results - FOXBusiness.com
... Wednesday, September 09, 2009 Vivus Shares Soar on Diet Drug Results ...Shares of small drug company Vivus (VVUS) soared more than...exceed expectations at all dose levels. Vivus said that its...
News: Vivus Eligible to Receive Milestone Payment of $140M from KV Pharmaceutical.
... Jul 30 2007, 11:36 AM EST Vivus Eligible to Receive Milestone Payment...Pharmaceutical GEN News Highlights Vivus received FDA approval...approved by the FDA, reports the company. Vivus previously announced an...
